OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Cuts Stock Holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC reduced its holdings in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 51.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 22,284 shares of the biopharmaceutical company's stock after selling 23,985 shares during the period. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC's holdings in Ultragenyx Pharmaceutical were worth $937,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of RARE. Van ECK Associates Corp grew its stake in shares of Ultragenyx Pharmaceutical by 18.4% in the fourth quarter. Van ECK Associates Corp now owns 1,760 shares of the biopharmaceutical company's stock worth $74,000 after acquiring an additional 273 shares during the period. Wealth Enhancement Advisory Services LLC boosted its position in shares of Ultragenyx Pharmaceutical by 1.4% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 22,047 shares of the biopharmaceutical company's stock worth $928,000 after acquiring an additional 294 shares during the last quarter. BOKF NA boosted its position in shares of Ultragenyx Pharmaceutical by 5.0% during the fourth quarter. BOKF NA now owns 7,976 shares of the biopharmaceutical company's stock worth $336,000 after acquiring an additional 382 shares during the last quarter. Smartleaf Asset Management LLC raised its stake in Ultragenyx Pharmaceutical by 259.5% during the fourth quarter. Smartleaf Asset Management LLC now owns 683 shares of the biopharmaceutical company's stock valued at $29,000 after purchasing an additional 493 shares in the last quarter. Finally, Arizona State Retirement System raised its stake in Ultragenyx Pharmaceutical by 2.4% during the fourth quarter. Arizona State Retirement System now owns 24,038 shares of the biopharmaceutical company's stock valued at $1,011,000 after purchasing an additional 568 shares in the last quarter. 97.67% of the stock is owned by hedge funds and other institutional investors.

Ultragenyx Pharmaceutical Stock Down 0.1%

Shares of RARE traded down $0.05 during mid-day trading on Monday, hitting $35.56. 236,609 shares of the company's stock were exchanged, compared to its average volume of 823,869. The firm has a market cap of $3.36 billion, a price-to-earnings ratio of -5.61 and a beta of 0.34. The stock's 50-day simple moving average is $36.39 and its 200-day simple moving average is $41.64. Ultragenyx Pharmaceutical Inc. has a 52 week low of $29.59 and a 52 week high of $60.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($1.57) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.54) by ($0.03). Ultragenyx Pharmaceutical had a negative return on equity of 193.80% and a negative net margin of 101.60%. The firm had revenue of $139.29 million for the quarter, compared to analyst estimates of $145.98 million. During the same quarter in the prior year, the business posted ($2.03) EPS. The business's revenue was up 28.0% on a year-over-year basis. Analysts forecast that Ultragenyx Pharmaceutical Inc. will post -5.18 earnings per share for the current fiscal year.

Insider Activity at Ultragenyx Pharmaceutical

In other Ultragenyx Pharmaceutical news, CFO Howard Horn sold 1,785 shares of Ultragenyx Pharmaceutical stock in a transaction dated Thursday, March 6th. The stock was sold at an average price of $40.40, for a total transaction of $72,114.00. Following the completion of the transaction, the chief financial officer now owns 106,169 shares of the company's stock, valued at $4,289,227.60. The trade was a 1.65% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Karah Herdman Parschauer sold 2,990 shares of Ultragenyx Pharmaceutical stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $42.88, for a total value of $128,211.20. Following the sale, the executive vice president now owns 54,991 shares of the company's stock, valued at approximately $2,358,014.08. This trade represents a 5.16% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 125,405 shares of company stock worth $5,285,169 over the last ninety days. Insiders own 5.50% of the company's stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on RARE. HC Wainwright reissued a "buy" rating and issued a $95.00 target price on shares of Ultragenyx Pharmaceutical in a research note on Friday, February 14th. Piper Sandler reduced their target price on Ultragenyx Pharmaceutical from $140.00 to $115.00 and set an "overweight" rating for the company in a research note on Monday, March 17th. Canaccord Genuity Group raised their target price on Ultragenyx Pharmaceutical from $121.00 to $136.00 and gave the company a "buy" rating in a research report on Tuesday, February 18th. JPMorgan Chase & Co. lifted their price objective on Ultragenyx Pharmaceutical from $104.00 to $117.00 and gave the stock an "overweight" rating in a report on Thursday, March 27th. Finally, Cantor Fitzgerald restated an "overweight" rating and set a $118.00 price target on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, February 26th. One analyst has rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $90.93.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.